导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.96% | 3038/4773 |
| 近一周 | -2.06% | 1145/5462 |
| 近一月 | -3.90% | 2061/5421 |
| 近一季 | -7.22% | 2337/5209 |
| 近半年 | -0.08% | 1227/4920 |
| 近一年 | -0.98% | 2813/4366 |
| 近两年 | 35.82% | 2057/2954 |
| 近三年 | 24.86% | 1283/2253 |
| 成立以来 | 41.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.38% 3611/4961 |
8.82% 2533/5312 |
- - |
- - |
| 2025 | 16.63% 2432/4813 |
-0.78% 2408/3635 |
2.45% 1559/4076 |
12.47% 3072/4524 |
2.02% 1112/4813 |
| 2024 | 19.21% 545/3463 |
4.85% 425/2808 |
0.32% 633/3014 |
16.91% 1314/3129 |
-3.06% 2245/3463 |
| 2023 | -7.72% 944/2656 |
1.63% 1537/2280 |
-3.79% 900/2385 |
1.33% 316/2515 |
-6.87% 1953/2655 |
| 2022 | -14.74% 389/2207 |
-12.13% 576/1919 |
9.14% 296/2016 |
-11.91% 610/2113 |
0.93% 1426/2208 |
| 2021 | -8.88% 1060/1822 |
-2.23% 604/1255 |
1.94% 1028/1330 |
-9.88% 1197/1466 |
1.45% 930/1822 |
| 2020 | 32.95% 468/1250 |
-10.36% 772/1028 |
12.98% 657/1067 |
12.67% 370/1164 |
16.50% 166/1184 |
| 2019 | 40.58% 250/1092 |
24.01% 533/754 |
4.48% 27/804 |
1.40% 404/850 |
7.01% 505/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.15% 414/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实富时中国A50ETF联接C VS. 长安沪深300非周期A(740101) |